Cartesian Therapeutics enrolls first patient in Phase 3 AURORA trial of Descartes-08 for myasthenia gravis

Cartesian Therapeutics, Inc.

First participant enrolled in randomized, placebo-controlled Phase 3 AURORA trial of Descartes-08 (CAR-T) in ~100 patients with AChR Ab+ myasthenia gravis.
Descartes-08 is administered outpatient without preconditioning chemotherapy; primary endpoint is proportion with MG-ADL improvement ≥3 points at Month 4.
Phase 2b data cited: average 4.8-point MG-ADL reduction at Month 12; in biologic-naive subgroup 7.1-point reduction and 57% minimal symptom expression.
Safety profile consistent with prior data; continues to support outpatient administration without integrating vectors or conditioning chemotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.